Jazz Pharmaceuticals plc (JAZZ) — Fair Value Analysis

Base-case fair value (P50): $289.06 · Current price: $251.58 · Verdict: Fairly Valued

The Verdict on JAZZ

Based on our Monte Carlo simulations, JAZZ PHARMACEUTICALS PLC (JAZZ) is currently deemed Fairly Valued. The stock trades at $251.58, while our median fair value (P50) stands at $289.06. This implies a projected +14.9% upside to its fair value, indicating the market price is largely aligned with our calculated intrinsic value, despite offering a modest potential return. This valuation aligns with JAZZ's strong operational and financial health.

How JAZZ stacks up against peers

JAZZ demonstrates a strong quality tier, reflecting robust operational and financial health within its market. While we don't compare it to a specific sector given the data provided, this strong underlying quality provides a solid foundation for its valuation. The observed +14.9% gap between the current trading price of $251.58 and our $289.06 fair value suggests that the market has largely priced in the company's fundamental strengths and future prospects without significant undervaluation or overvaluation.

What this means for investors

For investors considering JAZZ, the "Fairly Valued" verdict, alongside a strong quality tier, suggests that the current price of $251.58 offers a reasonable entry point, aligning closely with its intrinsic worth. The Monte Carlo P50 fair value of $289.06 indicates a +14.9% potential return, which, while positive, is not substantial enough to categorize it as significantly undervalued. This makes JAZZ a candidate for long-term holders focused on quality at a fair price. Sign up for FairCurve to see the full bear/bull distribution and track JAZZ's fair value as new fundamentals are released.